• Are We Targeting the Disease or Just the Diagnosis?

    October 30, 2026

    Drug target discovery often begins with a disease diagnosis. Your team has identified genetic associations, shortlisted candidate genes, and started assessing which targets deserve further investigation. But a diagnosis is not a complete representation of disease biology. Patients with the same condition can have different underlying molecular mechanisms, while diseases classified separately may share genetic […]

  • Exploring new therapeutic opportunities in psoriasis

    October 29, 2026

    Modern psoriasis therapies have transformed patient care. From TNF inhibitors such as etanercept (approved for psoriasis in 2004) and infliximab (2006) to secukinumab (2015, targeting IL17A) and guselkumab (2017, targeting IL23A), advances in understanding disease biology have led to more targeted treatments. Their success raises a question: how can we build on what we already […]

  • Potential Biomarkers for Parkinson’s Disease: What Else Could They Reveal?

    October 19, 2026

    What if a blood test could identify people at increased risk of Parkinson’s disease years before diagnosis? Large-scale proteomics studies are bringing that possibility closer. But when we explored 38 proteins associated with future Parkinson’s disease, their strongest disease associations turned out not to be neurological at all. In 2025, Gan and colleagues published a […]

  • Introducing GTAP: A Gene’s Disease Fingerprint, at a Glance

    September 22, 2026

    Every gene in DISGENET is linked to one or more diseases or phenotypes — for some genes, just one; for others, hundreds. Scrolling through those associations tells you what a gene is associated with, but not the more interesting question: what kind of disease profile does that gene have? At the extremes, two very different […]

  • Deeper Context, Sharper Signal: What’s New in DISGENET v26.3

    September 22, 2026

    In this article, we cover: Every DISGENET release adds new ways to see the biology behind a gene–disease or variant–disease association. v26.3 continues that trend with three additions: a new way to profile a gene’s therapeutic relevance, richer context on the evidence behind each association, and a more precise vocabulary for describing how genes and […]

  • Introducing the DISGENET MCP Connector: Making Our Data Native to AI Agents

    July 16, 2026

    In this post, we will cover: For more than a decade, DISGENET has given researchers and pharma teams a way to systematically explore gene-disease associations and scores that can be traced back to their evidence. Today, we’re extending that same trusted data to a new kind of user: the AI agent. Researchers are increasingly turning […]

  • A Complete Guide to DISGENET Scores

    June 17, 2026

    When you search DISGENET, you’re not just retrieving associations; you’re working with evidence. And evidence needs to be weighed, compared, and understood in context. That’s what DISGENET’s scoring metrics are designed to help you do. In this article, we cover: The GDA Score and VDA Score: Your Starting Point The GDA Score (Gene–Disease Association) and […]

  • Evidence Through Time: What’s New in DISGENET v26.2

    June 9, 2026

    In this article, we cover: Scientific knowledge doesn’t arrive fully formed. It accumulates — study by study, source by source, year by year. The question isn’t just what the evidence says today, but how it got there, and how confident you should be at any point in that journey. DISGENET v26.2 is built around that […]

  • From Data to Decision: What’s New in DISGENET v26.1

    April 17, 2026

    Full Traceability: Know Exactly Where Every Association Comes From In research and drug discovery, the source of an association matters as much as the association itself. Provenance — the ability to trace each gene–disease or variant–disease association back to its original database, publication, or evidence type — is what transforms a data point into a […]

  • Advancing Knowledge Extraction in DISGENET v26.1

    April 1, 2026

    The latest update to DISGENET (v26.1) represents a significant step forward in extracting biomedical knowledge from scientific publications. This release is powered by an enhanced Relation Extraction (RE) model operating within a sophisticated, end-to-end NLP pipeline engineered for precision and scale. This system translates millions of biomedical publications into a structured network of gene/variant–disease relationships, […]